Phase 1 Dose Escalation Study of BAY 1841788 in Japanese Metastatic Castration-resistant Prostate Cancer (mCRPC) Subjects
The primary objectives of this study are to investigate the safety and tolerability of BAY 1841788 in Japanese subjects with metastatic castration-resistant prostate cancer (mCRPC) and the PK of BAY 1841788 and its major metabolite BAY 1896953.
Prostatic Neoplasms
DRUG: BAY 1841788(ODM-201)
Number of participants with Treatment Emergent Adverse Event as measure of safety and tolerability, Up to 12 weeks|The intensity of an adverse event graded using the NCI CTCAE version 4.03, National Cancer Institute Common Terminology Criteria for Adverse Events Version 4.03 (NCI CTCAE), Up to 12 weeks|Plasma concentration of BAY 1841788 characterized by Cmax, Cmax: maximum drug concentration in plasma after single dose administration, Day -5 {pre dose, 0.5,1,1.5,3,5 ,8,12,24,36,48},Day -2 {before morning dose, 0.5,1,1.5,3,5,8, 12, 24, 36 and 48 h} ,Day 7 {before morning dose, 0.5, 1, 1.5,3,5,8,12 h (before evening dose)}|Plasma concentration of BAY 1841788 characterized by tmax, tmax: time to reach maximum drug concentration in plasma after single (first) dose, Day -5 {pre dose, 0.5,1,1.5,3,5 ,8,12,24,36,48},Day -2 {before morning dose, 0.5,1,1.5,3,5,8, 12, 24, 36 and 48 h} ,Day 7 {before morning dose, 0.5, 1, 1.5,3,5,8,12 h (before evening dose)}|Plasma concentration of BAY 1841788 characterized by AUC(0-12), AUC(0-12):AUC from time 0 to 12 hours after administration, Day -5 {pre dose, 0.5,1,1.5,3,5 ,8,12,24,36,48},Day -2 {before morning dose, 0.5,1,1.5,3,5,8, 12, 24, 36 and 48 h} ,Day 7 {before morning dose, 0.5, 1, 1.5,3,5,8,12 h (before evening dose)}|Plasma concentration of metabolite BAY 1896953 characterized by Cmax, Cmax: maximum drug concentration in plasma after single dose administration, Day -5 {pre dose, 0.5,1,1.5,3,5 ,8,12,24,36,48},Day -2 {before morning dose, 0.5,1,1.5,3,5,8, 12, 24, 36 and 48 h} ,Day 7 {before morning dose, 0.5, 1, 1.5,3,5,8,12 h (before evening dose)}|Plasma concentration of metabolite BAY 1896953 characterized by tmax, tmax: time to reach maximum drug concentration in plasma after single (first) dose, Day -5 {pre dose, 0.5,1,1.5,3,5 ,8,12,24,36,48},Day -2 {before morning dose, 0.5,1,1.5,3,5,8, 12, 24, 36 and 48 h} ,Day 7 {before morning dose, 0.5, 1, 1.5,3,5,8,12 h (before evening dose)}|Plasma concentration of metabolite BAY 1896953 characterized by AUC(0-12), AUC(0-12):AUC from time 0 to 12 hours after administration, Day -5 {pre dose, 0.5,1,1.5,3,5 ,8,12,24,36,48},Day -2 {before morning dose, 0.5,1,1.5,3,5,8, 12, 24, 36 and 48 h} ,Day 7 {before morning dose, 0.5, 1, 1.5,3,5,8,12 h (before evening dose)}|Plasma concentration of diastereomers BAY 1896951 characterized by Cmax, Cmax: maximum drug concentration in plasma after single dose administration, Day -5 {pre dose, 0.5,1,1.5,3,5 ,8,12,24,36,48},Day -2 {before morning dose, 0.5,1,1.5,3,5,8, 12, 24, 36 and 48 h} ,Day 7 {before morning dose, 0.5, 1, 1.5,3,5,8,12 h (before evening dose)}|Plasma concentration of diastereomers BAY 1896951 characterized by tmax, tmax: time to reach maximum drug concentration in plasma after single (first) dose, Day -5 {pre dose, 0.5,1,1.5,3,5 ,8,12,24,36,48},Day -2 {before morning dose, 0.5,1,1.5,3,5,8, 12, 24, 36 and 48 h} ,Day 7 {before morning dose, 0.5, 1, 1.5,3,5,8,12 h (before evening dose)}|Plasma concentration of diastereomers BAY 1896951 characterized by AUC(0-12), AUC(0-12):AUC from time 0 to 12 hours after administration, Day -5 {pre dose, 0.5,1,1.5,3,5 ,8,12,24,36,48},Day -2 {before morning dose, 0.5,1,1.5,3,5,8, 12, 24, 36 and 48 h} ,Day 7 {before morning dose, 0.5, 1, 1.5,3,5,8,12 h (before evening dose)}|Plasma concentration of diastereomers BAY 1896952 characterized by Cmax, Cmax: maximum drug concentration in plasma after single dose administration, Day -5 {pre dose, 0.5,1,1.5,3,5 ,8,12,24,36,48},Day -2 {before morning dose, 0.5,1,1.5,3,5,8, 12, 24, 36 and 48 h} ,Day 7 {before morning dose, 0.5, 1, 1.5,3,5,8,12 h (before evening dose)}|Plasma concentration of diastereomers BAY 1896952 characterized by tmax, Day -5 {pre dose, 0.5,1,1.5,3,5 ,8,12,24,36,48},Day -2 {before morning dose, 0.5,1,1.5,3,5,8, 12, 24, 36 and 48 h} ,Day 7 {before morning dose, 0.5, 1, 1.5,3,5,8,12 h (before evening dose)}, tmax: time to reach maximum drug concentration in plasma after single (first) dose|Plasma concentration of diastereomers BAY 1896952 characterized by AUC(0-12), AUC(0-12):AUC from time 0 to 12 hours after administration, Day -5 {pre dose, 0.5,1,1.5,3,5 ,8,12,24,36,48},Day -2 {before morning dose, 0.5,1,1.5,3,5,8, 12, 24, 36 and 48 h} ,Day 7 {before morning dose, 0.5, 1, 1.5,3,5,8,12 h (before evening dose)}
The drug product is licensed from Orion pharma, Finland which is also the manufacturer of the product.